Notably, pharmaceutical agents modulating the activity of ER, AR, RAR, and GR are presently employed in the treatment regimens for breast cancer, prostate cancer, APL, and acute lymphoblastic leukemia, respectively [18, 126]. This evidence concerns the gene AR and prostate carcinoma.